Start triage first, then route to emergency care.
Need urgent help? Start triage first, then route to emergency care.
Roxee Medication Guide
Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.
Veterinary professional?
These are the reference facts Roxee uses on browse cards and quick facts.
Sponsor, product, and application records imported from Animal Drugs @ FDA.
openFDA reaction terms and case summaries are supporting evidence, not proof of causality.
Drug type: Generic ingredient • Branded profile • FDA branded products available
Species: Both
Manufacturer: Multiple FDA labelers
Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.
For the control of pain and inflammation associated with osteoarthritis. For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration when administered prior to surgery. For the control of pain and inflammation associated with osteoarthritis in dogs. Species commonly shown: Both, Dog, Cat.
For the control of pain and inflammation associated with osteoarthritis. For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration when administered prior to surgery. For the control of pain and inflammation associated with osteoarthritis in dogs.
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For oral use in dogs only. Do not use in cats. Acute renal failure and death have been associated with the use of meloxicam in cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Top reported reactions (openFDA): Vomiting, Diarrhoea, Lethargy (see also Central nervous system depression in 'Neurological'), Anorexia, Death by euthanasia, Death.
Choose a pet, confirm current or past, and optionally add reminder notes.
Sign in to save this medication to your pet profile.
Sign in to continueStart here first for the safest next-step summary before the deeper medication detail.
Used for:
Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Dosing note:
Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.
What to watch for:
When to call the vet:
Regulatory restrictions are shown in Vet View.
What to tell or ask your vet today:
A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.
Roxee has limited cited overview evidence for Meloxicam; use the official documents and your veterinarian's instructions for product-specific decisions.
32 tracked reaction signals; 32 reported cases; 24 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.
Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.
Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.
Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.
Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Blood in vomit (1 reports), Blood in urine (1 reports), Behavioral disorder (unspecified) (1 reports)
Digestive (3), Skin & allergy (3), Neurologic (1), Behavior (2)
Dog (16 reports), Cat (16 reports)
Domestic Shorthair (2), Retriever - Golden (2), Spaniel - King Charles Cavalier (2), Domestic Mediumhair (1). These are report metadata, not proof that a breed is at higher risk.
Verify whether Meloxicam fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.
Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.
For oral use in dogs only, Do not use in cats, Acute renal failure and death have been associated with the use of meloxicam in cats, Repeated use of meloxicam in cats has been associated with acute renal failure and death, Do not administer additional injectable or oral meloxicam to cats
Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.
Review status / Updated / Sources
Review status: Clinical reviewer not listed
Updated: February 12, 2026, 10:44 PM UTC
Side effects to monitor:
Most reported reactions:
Emergency warning signs:
Source-backed clinical checkpoints for quick review.
Official label facts first, then secondary summaries. Marketing content is separated below.
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For oral use in dogs only. Do not use in cats. Acute renal failure and death have been associated with the use of meloxicam in cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.
Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.
Received 2026-03-18 · MSK · MSK
Received 2026-03-16 · MSK · MSK
Received 2026-03-13 · MSK · MSK
Received 2026-02-24 · MSK · MSK
Received 2025-12-16 · MSK · MSK
Received 2025-12-16 · MSK · MSK
Received 2025-12-15 · MSK · MSK
Received 2025-12-04 · MSK · MSK
Tap or hover a reaction to see what it means in plain language.
| Reaction | Body system | Cases | Species | Serious cases |
|---|---|---|---|---|
| Neurologic | 1 | Dog | 1 | |
| Digestive | 1 | Cat | 1 | |
| Digestive | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Behavior | 1 | Cat | 1 | |
| Other | 1 | Cat | 1 | |
| Other | 1 | Dog | 1 | |
| Other | 1 | Dog | 1 |
Species coverage: Dog (16) Cat (16)
| Reaction | Body system | Species | Seriousness | Frequency | Reports |
|---|---|---|---|---|---|
| Neurologic | Dog | Serious | - | 1 | |
| Digestive | Cat | Serious | - | 1 | |
| Skin & allergy | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Skin & allergy | Dog | Non-serious | - | 1 | |
| Behavior | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Skin & allergy | Cat | Non-serious | - | 1 | |
| Other | Cat | Non-serious | - | 1 | |
| Digestive | Cat | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Behavior | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Non-serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Cat | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 | |
| Other | Dog | Serious | - | 1 |
The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.
Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.
Full source previews and metadata remain in the veterinary/professional layer.
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
Official label / PI · Labeling
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
Loxicom® oral suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on thefirst day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the control of pain and inflammation associated with osteoarthritis in dogs.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the control of pain and inflammation associated with osteoarthritis.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the control of pain and inflammation associated with osteoarthritis in dogs.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
For the control of pain and inflammation associated with osteoarthritis.
Meloxicam injection should be administered initially as a single dose, at0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.
For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery.
Administer a single, one-time subcutaneous dose of Meloxicam injection to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated. To ensure accuracy of dosing, the use of a 1 mL graduated syringe is recommended.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
Administer initially as a single dose at 0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045 mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.
For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery.
Administer a single, one-time subcutaneous dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated.
Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · SPL
Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
SPL · Structured Product Label
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
FOI · FOI
Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.
Quick facts and links to official labeling and safety signals.
Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.
Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.
| Package NDC | Product NDC | Form / Route | Status |
|---|---|---|---|
| 0010-6013-01 | 0010 | - | |
| 0010-6014-01 | 0010 | - | |
| 0010-6014-02 | 0010 | - | |
| 0010-6015-01 | 0010 | - | |
| 0010-6015-02 | 0010 | - | |
| 0010-6015-03 | 0010 | - | |
| 0010-6015-04 | 0010 | - | |
| 11695-6936-1 | 11695 | - | |
| 11695-6936-2 | 11695 | - | |
| 11695-6966-1 | 11695 | - | |
| 11695-6966-2 | 11695 | - | |
| 11695-6966-3 | 11695 | - | |
| 11695-6966-4 | 11695 | - | |
| 11695-7008-1 | 11695 | - | |
| 11695-7008-2 | 11695 | - | |
| 11695-7050-1 | 11695 | - | |
| 11695-7067-1 | 11695 | - | |
| 11695-7067-2 | 11695 | - | |
| 13744-505-01 | 13744 | - | |
| 13744-505-10 | 13744 | - |
Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.
Every non-trivial field is expected to include provenance and update timestamps.
Official sponsor/proprietary-name/application-status records linked by active ingredient.
| Product | Sponsor | Application | Status | Published |
|---|---|---|---|---|
|
Meloxicam Oral Suspension
RX
Meloxicam
Oral Suspension
• Oral
|
ZyVet Animal Health, Inc. | ANADA 200-856 | Approved | Jul 1, 2026 |
|
Loxicom®
RX
Meloxicam
Oral Suspension
• Oral
|
Norbrook Laboratories, Ltd. | ANADA 200-786 | Approved | Jun 30, 2026 |
|
Meloxisol™
RX
Meloxicam
Oral Suspension
• Oral
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-794 | Approved | Aug 28, 2025 |
|
Meloxicam Oral Suspension
RX
Meloxicam
Oral Suspension
• Oral
|
Felix Pharmaceuticals Pvt. Ltd. | ANADA 200-817 | Approved | Jul 31, 2025 |
|
Meloxisol™
RX
Meloxicam
Oral Suspension
• Oral
|
Cronus Pharma Specialities India Private Ltd. | ANADA 200-816 | Approved | Jul 31, 2025 |
|
Meloxicam
RX
Meloxicam
Injectable Solution
• Intravenous, Subcutaneous
|
Felix Pharmaceuticals Pvt. Ltd. | ANADA 200-727 | Approved | Nov 7, 2024 |
|
Metacam® 5 mg/mL Solution for Injection
RX
Meloxicam
Liquid (Solution)
• Subcutaneous, Intravenous
|
Boehringer Ingelheim Animal Health USA, Inc. | NADA 141-219 | Approved | Mar 1, 2024 |
|
Metacam® Oral Suspension
RX
Meloxicam
Liquid (Suspension)
• Oral
|
Boehringer Ingelheim Animal Health USA, Inc. | NADA 141-213 | Approved | Dec 21, 2023 |
|
Meloxicam Injection
RX
Meloxicam
Sterile Solution
• Subcutaneous, Intravenous
|
Accord Healthcare, Inc. | ANADA 200-485 | Approved | Jan 31, 2023 |
|
Loxicom®
RX
Meloxicam
Solution For Injection
• Intravenous, Subcutaneous
|
Norbrook Laboratories, Ltd. | ANADA 200-491 | Approved | Aug 2, 2021 |
|
Meloxicam Solution for Injection
RX
Meloxicam
Sterile Solution
• Intravenous, Subcutaneous
|
Dechra Veterinary Products LLC | ANADA 200-540 | Approved | Aug 18, 2020 |
|
Loxicom®
RX
Meloxicam
Oral Suspension
• Oral
|
Norbrook Laboratories, Ltd. | ANADA 200-497 | Approved | Feb 27, 2019 |
|
Meloxidyl®
RX
Meloxicam
Oral Suspension
• Oral
|
Ceva Sante Animale | ANADA 200-550 | Approved | Dec 21, 2018 |
|
OroCAM® Transmucosal Oral Spray
RX
Meloxicam
Transmucosal Oral Spray
• Oral
|
Zoetis Inc. | NADA 141-346 | Approved | Nov 13, 2017 |
Data source: FDA Animal Drugs @ FDA (public search export).
Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.
Meloxicam Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
FDA page: Open in Animal Drugs @ FDA
Loxicom® oral suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on thefirst day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
FDA page: Open in Animal Drugs @ FDA
For the control of pain and inflammation associated with osteoarthritis in dogs.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
FDA page: Open in Animal Drugs @ FDA
For the control of pain and inflammation associated with osteoarthritis.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
FDA page: Open in Animal Drugs @ FDA
For the control of pain and inflammation associated with osteoarthritis in dogs.
Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatments after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.
FDA page: Open in Animal Drugs @ FDA
For the control of pain and inflammation associated with osteoarthritis.
Meloxicam injection should be administered initially as a single dose, at0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.
For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery.
Administer a single, one-time subcutaneous dose of Meloxicam injection to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated. To ensure accuracy of dosing, the use of a 1 mL graduated syringe is recommended.
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
Administer initially as a single dose at 0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045 mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.
For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy and castration when administered prior to surgery.
Administer a single, one-time subcutaneous dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated.
Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats.
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
FDA page: Open in Animal Drugs @ FDA
For the control of pain and inflammation associated with osteoarthritis. For the control of postoperative pain and inflammation associated with orthopedic surgery, ovariohysterectomy, and castration when administered prior to surgery. For the control of pain and inflammation associated with osteoarthritis in dogs.
Source: FDA Animal Drugs @ FDA • Reference
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For oral use in dogs only. Do not use in cats. Acute renal failure and death have been associated with the use of meloxicam in cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).
Showing top 5 for Digestive.
Showing top 5 for Skin & allergy.
Showing top 5 for Neurologic.
Showing top 5 for Behavior.
Showing top 5 for Other.
Data source: FDA openFDA Animal & Veterinary adverse event reports.
These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.
Cat, Domestic Shorthair, Female, 14 year, 6.895 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Licking, Localised hair loss, Skin scab, Elevated creatine-kinase, Medication error NOS • Outcome: Ongoing
Cat, Domestic Shorthair, Female, 6 month, 2.72 kilogram • Drug: MSK, Unknown • Reactions: Tongue ulceration • Outcome: Recovered/Normal
Cat, Domestic Mediumhair, Female, 6 month, 2.95 kilogram • Drug: MSK, Unknown • Reactions: Tongue ulceration • Outcome: Recovered/Normal
Dog, Retriever - Golden, Female, 13 year, 23.315 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Urinary tract infection, Lymphadenopathy, Elevated globulins, Abnormal cytology • Outcome: Ongoing
Dog, Retriever - Golden, Female, 2 year, 27.216 kilogram • Drug: MSK, Suspension, Oral, Dose: 2.70 Milligram per dose, Frequency: 24 per hour • Reactions: Vomiting, Loss of appetite, Azotaemia, Electrolyte disorder, Hypercortisolaemia… • Outcome: Ongoing
Dog, Crossbred Canine/dog, Male, 13 year • Drug: MSK, Suspension, Oral, Dose: 1 Unknown per animal • Reactions: Haematochezia, Anaemia NOS • Outcome: Outcome Unknown
Dog, Spaniel - King Charles Cavalier, Male, 9 year • Drug: MSK, Suspension, Oral, Dose: 1 Unknown per animal • Reactions: Haematochezia, Anaemia NOS • Outcome: Outcome Unknown
Dog, Spaniel - King Charles Cavalier, Female, 2 year • Drug: MSK, Suspension, Oral, Dose: 1 Unknown per animal • Reactions: Haematochezia, Anaemia NOS • Outcome: Outcome Unknown
Data source: FDA openFDA Animal & Veterinary adverse event reports.
No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.
No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.
Let others know your experience or advice regarding this medication.
This medication has not been reviewed by a veterinarian yet.